Suchergebnisse - "Guglielmetti, Lorenzo"

PubPharm (86)

21

Rifapentine access in Europe : growing concerns over key tuberculosis treatment component

enthalten in: The European respiratory journal | 2022

von Guglielmetti, L. | Günther, G. | Leu, C. | +14

CommentIn: Eur Respir J. 2022 Aug 25;60(2):. - PMID 35777762

22

Cost and availability of drugs and treatment regimens and availability of drug resistance testing for tuberculosis in Europe

enthalten in: bioRxiv.org | 2022

von Günther, G. | Guglielmetti, L. | Leu, C. | +2

23

Treatment for COVID-19-a cohort study from Northern Italy

enthalten in: Scientific reports | 2021

von Guglielmetti, L. | Aschieri, D. | Kontsevaya, I. | +16

24

Co-administration of treatment for rifampicin-resistant tuberculosis and chronic hepatitis C virus infection: a TBnet and ESGMYC study

enthalten in: bioRxiv.org | 2021

von Tunesi, S. | Le Du, D. | Gualano, G. | +15

25

Evidence-based Definition for Extensively Drug-Resistant Tuberculosis

enthalten in: American journal of respiratory and critical care medicine | 2021

von Roelens, M. | Battista Migliori, G. | Rozanova, L. | +15

CommentIn: Am J Respir Crit Care Med. 2021 Sep 15;204(6):629-631. - PMID 34375572

26

Impact of the revised definition of extensively drug-resistant tuberculosis

enthalten in: The European respiratory journal | 2021

von Veziris, N. | Bonnet, I. | Morel, F. | +11

27

Cardiac safety of multidrug-resistant tuberculosis treatment : moving towards individualised monitoring

enthalten in: The Lancet. Infectious diseases | 2021

von Hewison, C. | Guglielmetti, L.

CommentOn: Lancet Infect Dis. 2021 Jul;21(7):975-983. - PMID 33587897

28

Isoniazid-monoresistant tuberculosis in France : Risk factors, treatment outcomes and adverse events

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2021

von Bachir, M. | Guglielmetti, L. | Tunesi, S. | +77

29

The coming-of-age of bedaquiline : a tale with an open ending

enthalten in: The European respiratory journal | 2021

von Guglielmetti, L. | Varaine, F.

CommentOn: Eur Respir J. 2021 Jun 10;57(6):. - PMID 33334942

30

Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis : contribution of murine studies

enthalten in: The European respiratory journal | 2021

von Maitre, T. | Guglielmetti, L. | Veziris, N.

CommentOn: Eur Respir J. 2021 Mar 11;57(3):. - PMID 33154028